The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Calendar Problem. Here’s How Commercial Market Access Teams Can Stop Getting Blindsided.
If you work in commercial market access, you’ve probably felt it: the sudden shift from “we have time” to “we ha…

Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage is supposed to be the reward for taking the risk—betting on patent challenges, investing in launch readiness, and forcing the market to re-price ar…

The clock is ticking—and “true generic” timing is where deals are won or lost.
In pharma, everyone talks about exclusivity like it’s a static legal concept. But for anyone building a launch strategy, exclusivity is more like a live dashboard: patents e…

Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…

Generic entry isn’t just a legal milestone—it’s a market-shaping event. And the winners are often decided long before the drug ever goes off-patent.
When a blockbuster medicine approaches patent expiry, the real competition doesn’t begin on the day the…

Most people think “branded generic” is a contradiction. It isn’t. It’s a pricing strategy.
Here’s the uncomfortable truth: consumers often pay a “trust premium” for branded generics—not because the molecule is different, but because the experience is.
…

AI is quietly rewriting the competitive landscape in pharma—and your drug’s “story” is only as good as the data behind it.
If you’re in pharma, you’ve probably felt it: the market doesn’t just reward clinical outcomes anymore. It rewards narrative velo…

Most pharma teams don’t lose because they lack data—they lose because they don’t see the right data at the right time.
That’s the uncomfortable truth behind the “intelligence gap” many organizations quietly accept: they track patents, but they don’t op…

Two systems. One fight. How the “patent dance” and Orange Book linkage are shaping the $400B biologics war.
In the biologics market, the real competition doesn’t start when a drug hits the shelf. It starts years earlier—inside a procedural maze where t…

Most pharma teams don’t lose because they can’t innovate. They lose because they’re late.
Late to spot when exclusivity is actually ending. Late to understand what’s expiring—and what’s not. Late to model the competitive impact of an ANDA, a 505(b)(2),…